Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 6, 2013, Pages 698-705

  Ricotti, Valeria ^a   Ridout, Deborah A ^a   Scott, Elaine ^b   Quinlivan, Ros ^a,c   Robb, Stephanie A ^a   Manzur, Adnan Y ^a   Muntoni, Francesco ^a,c   On Behalf of the NorthStar Clinical Network, ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Muscular Dystrophy Campaign   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFLAZACORT; PREDNISOLONE;

ADOLESCENT; AGGRESSIVENESS; ANGER; ARTICLE; BEHAVIOR DISORDER; BODY HEIGHT; BODY MASS; BONE DENSITY; CATARACT; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHINGOID SYNDROME; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; FRACTURE; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERTENSION; INCREASED APPETITE; INSOMNIA; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MOBILIZATION; MOOD CHANGE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHYSIOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SKIN BRUISING; SPINE FRACTURE; TREATMENT DURATION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84877594408     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-303902     Document Type: Article

References (41)

1. Emery AE. Population frequencies of inherited neuromuscular diseases - a world survey. Neuromuscul Disord 1991;1:19-29.
2. Drousiotou A, Ioannou P, Georgiou T, et al. Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test 1998;2:55-60.
3. Emery AE. The muscular dystrophies. Lancet 2002;359:687-95. (Pubitemid 34203773)
4. Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;1:CD003725.
5. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
6. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-89.
7. Fisher I, Abraham D, Bouri K, et al. Prednisolone-induced changes in dystrophic skeletal muscle. Faseb J 2005;19:834-6.
8. Griggs RC, Moxley RT, Mendell JR, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991;48:383-8.
9. Beenakker EA, Fock JM, Van Tol MJ, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol 2005;62:128-32. (Pubitemid 40105045)
10. Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011;77:444-52.
11. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-7. (Pubitemid 19154573)
12. Fenichel GM, Florence JM, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-7.
13. Dubowitz V. Prednisone in Duchenne dystrophy. Neuromuscul Disord 1991;1:161-3.
14. Bushby K, Muntoni F, Urtizberea A, et al. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 2004;14:526-34. (Pubitemid 39141708)
15. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000;23:1344-7.
16. Leiden Muscular Dystrophy pages. Center for Human and Clinical Genetics, LUMC. http://www.dmd.nl (accessed 3 Dec 2012)
17. NSCN. NorthStar Ambulatory Assessment. Secondary NorthStar Ambulatory Assessment 2006. http://www.muscular-dystrophy.org/assets/0002/5040/North-Star- Ambulatory-assessment.pdf (accessed 3 Dec 2012)
18. Scott E, Eagle M, Mayhew A, et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 2012;17:101-9.
19. Mazzone E, Messina S, Vasco G, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 2009;19:458-61.
20. Mazzone E, Martinelli D, Berardinelli A, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010;20:712-16.
21. Mayhew A, Cano S, Scott E, et al. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 2011;53:535-42.
22. Mazzone E, Vasco G, Sormani MP, et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 2011;77:250-6.
23. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011;378:595-605.
24. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377-99.
25. Cole TJ. Growth monitoring with the British 1990 growth reference. Arch Dis Child 1997;76:47-9. (Pubitemid 27060492)
26. Quinlivan R, Shaw N, Bushby K. 170th ENMC International Workshop: Bone Protection for Corticosteroid Treated Duchenne Muscular Dystrophy. 27-29 November 2009, Naarden, The Netherlands. Neuromuscul Disord 2010;20:761-9.
27. Biggar WD, Harris VA, Eliasoph L, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-55.
28. McDonald CM, Han JJ, Mah JK, et al. Corticosteroids and Duchenne muscular dystrophy: does earlier treatment really matter? Muscle Nerve 2012;45:777-9.
29. Merlini L, Gennari M, Malaspina E, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 2012;45:796-802.
30. Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 2000;20:71-4. (Pubitemid 30013402)
31. Bianchi ML, Mazzanti A, Galbiati E, et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 2003;14:761-7. (Pubitemid 37295839)
32. Bianchi ML, Biggar D, Bushby K, et al. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord 2011;21:298-303.
33. Mayo AL, Craven BC, McAdam LC, et al. Bone health in boys with Duchenne muscular dystrophy on long-term daily deflazacort therapy. Neuromuscul Disord 2012;22:1040-5.
34. King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007;68:1607-13. (Pubitemid 46717986)
35. Moxley RT, Pandya S. Weekend high-dosage prednisone: a new option for treatment of Duchenne muscular dystrophy. Neurology 2011;77:416-17.
36. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-18. (Pubitemid 26136714)
37. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86. (Pubitemid 30419053)
38. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004;363:1728-31. (Pubitemid 38670333)
39. Avorn J. In defense of pharmacoepidemiology - embracing the yin and yang of drug research. N Engl J Med 2007;357:2219-21. (Pubitemid 350190751)
40. Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ 2009;338:b81.
41. Bushby K, Griggs R. FOR DMD: Finding the optimum regimen for DMD. An NIH funded trial of steroids. 2011. http://www.parentprojectmd.org/site/DocServer/ 7-8-11-Bushby.pdf?docID=11610 (accessed 3 Dec 2012)